Why Did Altaris Acquire Simulations Plus?

On June 16, 2026, healthcare private equity firm Altaris announced an agreement to acquire Simulations Plus for approximately $375 million in cash. Simulations Plus is a drug development software provider, specializing in model-informed and AI-accelerated drug development advancing biopharma innovation.

According to Altaris, the transaction will transition Simulations Plus into a privately held entity and result in its delisting from the Nasdaq Global Select Market. Simulations Plus shareholders will receive $18.50 per share in cash, representing a 26 percent premium over the 60-day average share price.

“The life sciences industry is at an inflection point, as software and services are rapidly evolving toward integrated, AI-driven platforms, cloud-based infrastructure, and more predictable, subscription-based business models. This transaction provides immediate and certain value to Simulations Plus stockholders, and we believe the transaction will better position us to serve our customers and accelerate innovation across product offerings.” said Shawn O’Connor, Chief Executive Officer of Simulations Plus.

Platform Integration and Synergy

As per Altaris, the transaction is part of its broader commitment to investing in digital health, health imaging, and generics sectors. Simulations Plus will be combined with Chemical Computing Group after the closing of the transaction.

Chemical Computing Group is an existing portfolio company of Altaris that provides computer-aided molecular design software for the pharmaceutical, biotechnology, and crop sciences industries.

The company also said that combining Simulations Plus and CCG unites two established providers of scientific computational drug development software, and noted that the two organizations share similar corporate cultures and serve an overlapping client base.

Simulations Plus provides modeling and simulation software utilized by pharmaceutical companies, biotechnology firms, consumer goods companies, and regulatory agencies, assisting organizations with drug discovery, development research, and regulatory submissions.

The company expects the transaction to close in the fourth quarter of 2026, subject to customary closing conditions and shareholder approval, and the headquarters of Simulations Plus are to remain in Research Triangle Park, North Carolina, following the completion of the acquisition.

Following the closing, the combined entities are projected to expand their service offerings to existing global pharmaceutical and biotechnology clients.